The Cochrane database of systematic reviews··
Antidepressants compared to placebo for generalized anxiety disorder
Updated
Abstract
The review included 37 unique randomized controlled trials with 12,226 participants.
- Antidepressants show a 41% higher rate of treatment response compared to placebo, as measured by a significant reduction in anxiety symptoms.
- The number needed to treat for an additional beneficial outcome is 7, indicating that approximately 7 patients need to be treated with antidepressants for one to experience significant improvement.
- There is no difference in overall acceptability between antidepressants and placebo, as measured by dropout rates during trials.
- Fewer participants discontinued treatment due to a lack of efficacy in the antidepressant group compared to the placebo group, with a number needed to treat of 27.
- However, more participants dropped out due to adverse effects in the antidepressant group, with a number needed to treat for an additional harmful outcome of 17.
- High certainty of evidence supports these findings across different classes of antidepressants.
Simplified
BACKGROUND: Generalised anxiety disorder (GAD) is a mental health condition characterised by excessive anxiety and worry about everyday events. GAD is a common disorder and generally affects women twice as often as men. Treatments include various psychological and pharmacological therapies. Among the pharmacological therapies, antidepressants, in particular, selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs), are commonly used for the treatment of GAD and many studies have shown their benefit over placebo. Only one systematic review and meta-analysis comparing all antidepressants to placebo has been done in the past. Since then, new data on existing antidepressants have emerged and new antidepressants have been introduced. An updated and more comprehensive review is needed to provide a stronger understanding of the efficacy, acceptability, tolerability, and impact on the quality of life of the various types of antidepressants compared to placebo.
OBJECTIVES: To assess the effects of antidepressants in GAD in adults, specifically: to determine the efficacy of antidepressants in alleviating symptoms of GAD compared to placebo and to review the acceptability of antidepressants in GAD in terms of adverse effects, including the general prevalence of adverse effects compared to placebo.
SEARCH METHODS: We searched the Cochrane Common Mental Health Disorders (CCMD) register, CENTRAL, MEDLINE, Embase, PsycINFO, and two trials registers in October 2022.
SELECTION CRITERIA: We included randomised controlled trials (RCT) or cluster-RCTs that randomly assigned participants to receive either an antidepressant or placebo for the treatment of GAD. There were no restrictions on dose, frequency, intensity, or duration of treatment. The studies included adults of either sex with a primary diagnosis of GAD and without any serious medical comorbidities. Psychiatric comorbidities were allowed as long as GAD was the primary diagnosis. We excluded studies investigating psychotherapies and those that included participants who had regular use of benzodiazepines. There were no restrictions on setting, country, or language.
DATA COLLECTION AND ANALYSIS: Two review authors independently checked eligibility and extracted data following standard Cochrane methodological procedures. We assessed risk of bias using the Cochrane RoB 1 tool. A third review author resolved disagreements between the two primary review authors. We extracted study characteristics, participant characteristics, intervention details, settings, and outcome measures regarding efficacy, acceptability, tolerability, and quality of life. We used GRADE to assess the certainty of the evidence.
MAIN RESULTS: We included 37 unique RCTs with 12,226 participants in the review. The studies included adults with moderate-severe GAD and without any serious medical comorbidities. Few studies included participants with secondary psychiatric comorbidities. The double-blind treatment duration ranged from four weeks to 28 weeks. Antidepressants have a benefit over placebo on rate of treatment response measured as a reduction of at least 50% on the Hamilton Anxiety Rating Scale (HAM-A) (risk ratio (RR) 1.41, 95% confidence interval (CI) 1.29 to 1.55; 20 studies, 7267 participants; high-certainty evidence). The magnitude of effect corresponds to a number needed to treat for an additional beneficial outcome (NNTB) of 7 (95% CI 5 to 9). Antidepressants have no difference in acceptability compared to placebo, measured as the number of participants who dropped out during the trial as a proportion of the total number of randomised participants (RR 1.03, 95% CI 0.93 to 1.14; 33 studies, 11,294 participants; high-certainty evidence). Fewer participants dropped out due to a lack of efficacy in the antidepressant group compared to the placebo group (RR 0.41, 95% CI 0.33 to 0.50; 29 studies, 11,007 participants; high-certainty evidence) with an NNTB of 27 (95% CI 24 to 32), and more participants dropped out due to adverse effects in the antidepressant group compared to placebo (RR 2.18, 95% CI 1.81 to 2.61; 32 studies, 11,793 participants; high-certainty evidence) with a number needed to treat for an additional harmful outcome (NNTH) of 17 (95% CI 13 to 112). We observed similar findings when classes of antidepressants were compared with placebo. The certainty of the evidence for the analyses comparing different classes of antidepressants to placebo was high.
AUTHORS' CONCLUSIONS: This review added to the growing literature on antidepressants in the treatment of GAD. We have high confidence that antidepressants are more effective than placebo at improving treatment response and that antidepressants have similar acceptability to placebo. Fewer participants dropped out due to a lack of efficacy in the antidepressant group compared to the placebo group and more participants dropped out due to adverse effects in the antidepressant group compared to placebo. We are highly confident in this evidence. This review identified some important gaps in the literature on antidepressants for GAD and can be used as a tool to guide future research. Future studies may be more transparent with their methodology and outcome reporting. Future reviews may also include people with comorbidities, and explore other sources of heterogeneity.
Related papers
Apr '18
Antidepressants compared to placebo for treating panic disorder in adults
cited by 27 papers
systematic review
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 29 papers
systematic review
Apr '18
Using antidepressants to treat depression in people with cancer
cited by 75 papers
systematic review
Nov '23
Comparing drug treatments for panic disorder in adults
cited by 13 papers
systematic review
Jul '17
Vortioxetine treatment for depression in adults
cited by 21 papers
systematic review
Apr '21
Antidepressant use in people with epilepsy and depression
cited by 19 papers
systematic review
Mar '25
Antidepressants for treating low back and leg pain from spine problems
cited by 5 papers
systematic review
Nov '14
Drug treatments for adults with somatoform disorders
cited by 92 papers
systematic review
Jun '15
Antidepressants for treating depression in people with cancer
cited by 31 papers
systematic review
Jan '18
Antidepressants for Treating Depression in Adults Living with HIV
cited by 25 papers
systematic review